Great Point Partners

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of therapies designed to degrade disease-causing proteins. The company’s lead product candidates include ARV-110, a proteolysis-targeting chimera (PROTAC) currently in phase I clinical trials for treating metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. Additionally, Arvinas is developing other PROTACs aimed at degrading various androgen receptor mutations and has initiatives focused on treating neurodegenerative diseases, including tauopathies. Arvinas collaborates with major pharmaceutical companies such as Pfizer, Genentech, Roche, and Bayer to advance its innovative therapeutic approaches. Founded in 2015, Arvinas is dedicated to improving the lives of patients with debilitating and life-threatening conditions through its unique protein degradation technology.

Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating treatments for diabetes. The company leverages its proprietary VIAdel technology to enhance the formulation of existing drugs, aiming to improve their efficacy and delivery. Biodel's lead product candidate is Linjeta, a rapid-acting mealtime insulin designed for individuals with Type I and Type II diabetes. In addition to Linjeta, the company is exploring earlier-stage candidates that include follow-on and second-generation rapid-acting insulins, a sublingual insulin tablet known as VIAtab, a line of basal insulins, and a glucagon formulation. Through its innovative approach, Biodel aims to address the needs of diabetes patients and improve their treatment options.